Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
Jennifer Shah(University of Pennsylvania), Katherine L. Nathanson(Translational Therapeutics (United States)), Dana Pueschl(University of Pennsylvania), Jake S. Shilan(University of Pennsylvania), Adam Kraya(Translational Therapeutics (United States)), Michael D. Feldman(University of Pennsylvania), Anna P. Hubert(University of Pennsylvania), Alba Llop Guevara(Vall d'Hebron Institut de Recerca), Catherine Ruan(University of Pennsylvania), Bradley Wubbenhorst(Translational Therapeutics (United States)), Kara N. Maxwell(Philadelphia VA Medical Center), Susan M. Domchek(University City Science Center), Anupma Nayak(University of Pennsylvania), Violeta Serra(Vall d'Hebron Institute of Oncology), Patrice J. Morin(National Institutes of Health), Judith Balmañà(Vall d'Hebron Hospital Universitari), Kurt D’Andrea(University of Pennsylvania), Mengyao Fan(University of Pennsylvania), John Pluta(Translational Therapeutics (United States)), Wenting Zhou(University of Pennsylvania)
Cited by 27
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k